B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

A literature review from 2021 found that as many as 12% of people with an EGFR mutation have a type called the exon 20 insertion mutation. If you have EGFR-positive lung cancer, it means your EGFR ...

The most common EGFR mutations in people with lung cancer are the EGFR exon 19 deletion mutation and EGFR exon 21 L858R point mutation. They respond to targeted therapies called EGFR inhibitors.

The CHMP has recommended Rybrevant (amivantamab) for use alongside carboplatin and pemetrexed chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon ...

The target enrollment for a global Phase 3 study of firmonertinib in first-line NSCLC patients with EGFR exon 20 insertion mutations has been achieved, and interim data shows encouraging results ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

Initiated a cohort to evaluate ORIC-114 monotherapy for the 1L treatment of patients with NSCLC harboring EGFR exon 20 insertion mutations. Announced the completion of the dose escalation portion ...

TAGRISSO is a prescription medication for adults with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. It is used to help prevent cancer recurrence after surgical ...